Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in R/R follicular lymphoma

Share :
Published: 12 Dec 2022
Views: 82
Dr Matthew Matasar - Rutgers Cancer Institute, New Brunswick, USA

Dr Matthew Matasar speaks to ecancer for ASH 2022 about a study he was involved in that looked at the safety and efficacy of mosunetuzumab monotherapy in relapsed/refractory follicular lymphoma patients who had received fewer than 2 lines of therapy.

He reports that the responses for the treatment remain durable with 80% of patients with a complete response still in a complete response 2 years after treatment.

Dr Matasar also reports that the progression free survival at 2 years was just greater than 50%.

At ASH we’ll be presenting our updated results for the study of mosunetuzumab monotherapy in patients with relapsed or refractory follicular lymphoma after two or more prior lines of therapy. We’ve previously reported the outcomes with mosunetuzumab monotherapy showing that this agent is both safe and highly effective in this patient population, but there remains an outstanding question of what the durability of response will be as our data mature, and we present such mature data this year at ASH.

With a median follow-up now exceeding two years at approximately 27 months, we do indeed see that the responses that patients have been enjoying do remain durable. For those that achieved a complete response, the ongoing duration of complete response there is no median yet achieved, with 80% of patients still in a CR two years after the completion of the treatment. Encouragingly, the PFS for the overall treated patients, again we do not have a median of duration yet reached, with a two year PFS just greater than 50%.

These results are very important for the community because, while we know that the activity of bispecific antibodies in this patient population is excellent, the durability remains an important question, particularly in the context of other therapeutic options that are available for our patients, including CAR T-cell therapy. As we gain a greater understanding of how deep and durable remissions following mosunetuzumab monotherapy will be, it will better position us as oncologists to discuss with our patients the relative options, particularly in the context of the anticipated approval by the FDA of mosunetuzumab by the end of this calendar year. Hope to see you at ASH to discuss these data in more detail.